IMBiotechnologies Signs Supply Agreement With Medicus Management

EDMONTON, AB / ACCESSWIRE / June 12, 2024 / IMBiotechnologies Ltd. ("IMBiotechnologies") has announced the signing of a supply agreement with Medicus Management, LLC ("Medicus"). Medicus is a group purchasing organization (GPO) supplying twenty office-based laboratory (OBL) and ambulatory surgical center (ASC) clinics specializing in minimally-invasive procedures.

"IMBiotechnologies' Ekobi® microspheres product is truly unique compared to the competitive embolic agents on the market," said J. Joseph Hewett, MD, President of Medicus. He noted that its biodegradability and ultrasound detectability features could improve the safety and efficacy of embolization, particularly in procedures like treating knee pain caused by osteoarthritis.

Michael Stewart, CEO of IMBiotechnologies, expressed excitement about collaborating with Medicus. "We are delighted with the opportunity to work with Medicus as they continue to grow in the ambulatory market," he said, emphasizing their focus on expanding the use of the Ekobi® Embolization Microsphere product.

Ekobi® Embolization Microspheres is a first-in-class, biodegradable embolic agent detectable by ultrasound. Approved in the US and Canada, it treats various hypervascularized tumors and conditions like uterine fibroids and enlarged prostates due to benign prostatic hyperplasia (BPH).